Elixir Capital closes trading window from Oct 1 for Q2FY27 results
- Trading window closed effective October 1, 2026
- Closure lasts until 48 hours after Q2FY27 results declaration
- Restriction applies to insiders, relatives, and external advisors

*this image is generated using AI for illustrative purposes only.
Elixir Capital Ltd has closed its trading window for dealing in company securities effective October 1, 2026. This closure is in anticipation of the declaration of un-audited financial results for the quarter and half year ended September 30, 2026.
The trading window will remain closed until 48 hours after the results are declared. The Board meeting to consider these standalone and consolidated results will be intimated separately in due course.
Regulatory compliance and restrictions
The closure adheres to the Company’s Code of Conduct to Regulate, Monitor and Report Trading by Insiders and SEBI (Prohibition of Insider Trading) Regulations, 2015. It also complies with BSE circular no. LIST/COMP/01/2019-20 dated April 2, 2019.
During this period, designated persons, directors, promoters, persons acting in concert, and employees are prohibited from trading in the company's securities. This restriction extends to their immediate relatives and any persons having contractual or fiduciary relations with the company.
Scope of restricted parties
The prohibition applies broadly to ensure market integrity during the sensitive period before earnings release. The following groups are explicitly barred from transactions:
- Directors, promoters, and persons acting in concert
- Employees and their immediate relatives
- Auditors, accountancy firms, law firms, analysts, and consultants
- Any person assisting or advising the company
The company filed this intimation with the BSE on September 24, 2026. The document was signed by Radhika Mehta, Whole-Time Director.
Historical Stock Returns for Elixir Capital
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.11% | +0.98% | +0.19% | +18.52% | -8.36% | +143.41% |
How might the upcoming Q2 and H1 FY27 financial results impact Elixir Capital's stock volatility once the trading window reopens?
Will the performance of Elixir Capital's NBFC peers influence investor sentiment ahead of the company's earnings declaration?
What specific credit quality metrics or asset quality trends are analysts expecting to see in the upcoming standalone and consolidated results?































